1,4-二硫杂-7-氮杂螺[4.4]壬烷 | 1003-80-1

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫代缩醛
• 中文名称: 1,4-二硫杂-7-氮杂螺[4.4]壬烷
• 中文别名: 1,4-二氧杂-7-氮杂螺[4.4]壬烷
• 英文名称: 3,3-Dithioethylenpyrrolidin
• 英文别名: 1,4-dithia-7-aza-spiro[4.4]nonane；1,4-Dithia-7-azaspiro[4.4]nonane
• CAS: 1003-80-1
• 化学式: C₆H₁₁NS₂
• mdl: MFCD08706176
• 分子量: 161.292
• InChiKey: RSZGQXYMUGKTME-UHFFFAOYSA-N

物化性质

• 沸点：
  285℃
• 密度：
  1.27
• 闪点：
  126℃

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  62.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,4-二硫杂-7-氮杂螺[4.4]壬烷 、 1,2-bis(chloromethyl)-4,5-methylenedioxybenzene 以 二氯甲烷 为溶剂， 反应 5.0h， 生成 5,7-dihydro-dispiro[[1,3]dioxolo[4,5-f]isoindolium-6,1'-pyrrolidinium-3',2''-[1,3]dithiolane]; chloride
  参考文献：
  名称：

  Levisalles,J.; Rose,E., Bulletin de la Societe Chimique de France, 1976, p. 1947 - 1952

  摘要：

  DOI：
• 作为产物：
  描述：

  1,4-dithia-7-aza-spiro[4.4]nonane-7-carboxylic acid ethyl ester 在 barium dihydroxide 作用下， 反应 16.0h， 生成 1,4-二硫杂-7-氮杂螺[4.4]壬烷
  参考文献：
  名称：

  Levisalles,J.; Rose,E., Bulletin de la Societe Chimique de France, 1976, p. 1947 - 1952

  摘要：

  DOI：

文献信息

• THERAPEUTIC COMPOUNDS
  申请人：CELGENE QUANTICEL RESEARCH, INC.

  公开号：US20180296543A1

  公开（公告）日：2018-10-18

  The present embodiments relate to substituted heterocyclic derivative therapeutic compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of diseases mediated by aberrant cell signalling, such as inflammatory disorders, cancer and neoplastic disease. Particular compounds described herein exhibit selective inhibitory activity against CBP compared with BRD4.

  本发明涉及取代杂环衍生物治疗性化合物，包括所述化合物的组合物，以及通过抑制溴结构域介导的乙酰赖氨酸蛋白区域（如组蛋白）的识别，来用于表观遗传调控的所述化合物和组合物。所述组合物和方法对于治疗由异常细胞信号介导的疾病，如炎症性疾病、癌症和肿瘤性疾病，是有用的。特别是，此处描述的某些化合物对CBP显示出相对于BRD4的选择性抑制活性。
• [EN] TREATING INCREASED INTRAOCULAR PRESSURE CAUSED BY STEROIDS
  申请人：SCHERING CORPORATION

  公开号：WO1987002585A2

  公开（公告）日：1987-05-07

  (EN) The rise in intraocular pressure associated with the use of steroidal anti-inflammatory drugs is controlled by use of angiotensin converting enzyme inhibitors. For the purposes of the invention, the preferred ACE inhibitor is 7-¨ADN-(1(S)-carboxy-3-phenylpropyl)-(S)-alanyl¨BD-1,4-dithia-7-azaspiro¨AD4.4¨BDnonane-8(S)-carboxylic acid.(FR) L'augmentation de la pression intra-oculaire associée à l'utilisation de médicaments stéroïdes anti-inflammatoires est contrôlée en utilisant des inhibiteurs d'une enzyme de conversion de l'angiotensine. Selon l'invention, l'inhibiteur préféré d'une enzyme de conversion de l'angiotensine est l'acide 7-¨ADN-(1(S)-carboxy-3-phénylpropyl)-(S)-alanyl¨BD-1,4-dithia-7-azaspiro¨AD4.4¨BDnonane-8(S)-carboxylique.

  使用类固醇类抗炎药物会导致眼内压力升高，但使用血管紧张素转换酶抑制剂可以控制。在本发明中，首选的血管紧张素转换酶抑制剂是7-¨ADN-(1(S)-羧基-3-苯基丙基)-(S)-丙氨酰¨BD-1,4-二硫-7-氮杂螺¨AD4.4¨BD-壬烷-8(S)-羧酸。
• Therapeutic compounds
  申请人：CELGENE QUANTICEL RESEARCH, INC.

  公开号：US10617680B2

  公开（公告）日：2020-04-14

  The present embodiments relate to substituted heterocyclic derivative therapeutic compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of diseases mediated by aberrant cell signalling, such as inflammatory disorders, cancer and neoplastic disease. Particular compounds described herein exhibit selective inhibitory activity against CBP compared with BRD4.

  本发明的实施方案涉及取代的杂环衍生物治疗化合物、包含所述化合物的组合物，以及所述化合物和组合物通过抑制溴化链介导的对蛋白质（如组蛋白）乙酰赖氨酸区的识别进行表观遗传调控的用途。所述组合物和方法可用于治疗由异常细胞信号介导的疾病，如炎症性疾病、癌症和肿瘤性疾病。与 BRD4 相比，本文所述的特定化合物对 CBP 具有选择性抑制活性。
• TREATING INCREASED INTRAOCULAR PRESSURE CAUSED BY STEROIDS
  申请人：SCHERING CORPORATION

  公开号：EP0246280A1

  公开（公告）日：1987-11-25
• BICYCLIC DERIVATIVES AS GABAA A5 RECEPTOR MODULATORS
  申请人：RICHTER GEDEON NYRT.

  公开号：US20210386718A1

  公开（公告）日：2021-12-16

  The present invention provides compounds of formula (I) and/or salt thereof and/or geometric isomer thereof and/or stereoisomer thereof and/or enantiomer thereof and/or racemate thereof and/or diastereomer thereof and/or biologically active metabolite thereof and/or prodrug thereof and/or solvate thereof and/or hydrate thereof and/or polymorph thereof having affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 and act as GABA A α5 negative allosteric modulators, thereby useful in the treatment or prevention of diseases related to the GABA A α5 receptor, process for the preparation thereof, pharmaceutical compositions comprising them alone or in combination with one or more other active ingredients and their use as medicaments.